OneOncology Showcases Research at 2024 ASCO Meeting

NASHVILLE, Tenn., May 30, 2024 – OneOncology, recognized as the fastest-growing platform for independent oncology practices, proudly presents significant research advancements made by its partner practices. These findings will be shared through 13 oral and poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled to take place from May 31 to June 4, 2024.

Highlighted Oral Presentations

Key presentations include groundbreaking studies on various patient populations. One crucial study, led by Dr. Todd Bauer from Tennessee Oncology, explores the long-term outcomes of lorlatinib versus crizotinib in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer. The CROWN study, focusing on a 5-year progression-free survival and safety profile, will be a significant highlight (Abstract: LBA8503).

Another notable presentation by Dr. Yuanbin Chen from The Cancer and Hematology Centers examines the consolidation treatment using durvalumab for patients with limited-stage small-cell lung cancer. This ADRIATIC study aims to provide insights into the effectiveness of this treatment (Abstract: LBA5).

Dr. Satish Shah from Pennsylvania Cancer Specialists and Research Institute will unveil Phase I/II study results on the safety and efficacy of the tissue factor-ADC MRG004A in patients with solid tumors, contributing to the development of new therapeutic avenues (Abstract: 3002).

Additionally, Dr. Kent Shih from Tennessee Oncology will present findings from the phase 2 RAGNAR trial, highlighting the safety and efficacy of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations (Abstract: 10002).

Commitment to Advancing Oncology

Ian W. Flinn, MD, PhD, Chief Scientific Officer of OneOncology, emphasizes the organization’s dedication to pushing the boundaries of oncology. "Our physician investigators are committed to advancing the field by expanding access to innovative research and novel therapeutic options for patients in their local communities," Dr. Flinn stated. He also noted the significance of the studies on bispecific antibodies, racial and ethnic diversity in clinical trials, and crucial findings in glioblastoma, non-small cell lung cancer, small cell lung cancer, and prostate cancer.

About OneOncology

Founded by community oncologists, OneOncology aims to enhance the lives of cancer patients by supporting independent community oncology practices. The organization strives to improve patient access to care in local communities while maintaining lower costs compared to hospital settings. OneOncology assists its network of practices through group purchasing, operational optimization, data analytics, practice growth, and clinical innovation.

Currently, OneOncology’s platform encompasses over 1,100 cancer care providers who serve approximately 750,000 patients across more than 400 care sites nationwide. Their collective efforts focus on maintaining the independence of community oncology practices and enabling them to deliver cutting-edge care.

In conclusion, OneOncology’s participation in the 2024 ASCO Annual Meeting underscores its commitment to pioneering research and enhancing therapeutic options for cancer patients. The presentations from its partner practices are poised to contribute significantly to the oncology field, driving forward the mission of improving cancer care across communities.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!